The phosphatidylinositol 3-kinase/Akt pathway regulates the HCCR-1 oncogene expression

被引:24
作者
Cho, Goang-Won
Shin, Seung Min
Namkoong, Hong
Kim, Hyun Kee
Ha, Seon-Ah
Hur, Soo Young
Kim, Tae Eung
Chai, Young-Gyu
Kim, Jin Woo [1 ]
机构
[1] Catholic Univ Korea, Coll Med, Mol Genet Lab, Seoul 137040, South Korea
[2] Catholic Univ Korea, Coll Med, Dept Obstet & Gynecol, Seoul 137040, South Korea
[3] Hanyang Univ, Coll Sci & Technol, Div Mol & Life Sci, Ansan 426791, South Korea
基金
新加坡国家研究基金会;
关键词
human cancer; promoter; LY-294002; homeodomain; K562;
D O I
10.1016/j.gene.2006.07.006
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
The human cervical cancer oncogene HCCR-1 is overexpressed in various human cancers, and might function as a negative regulator of the p53 tumor suppressor. To determine the regulatory pathway involved in the HCCR-1 gene expression, we searched the 5' flanking region of HCCR-1 and identified HCCR-1 promoter including putative homeodomain protein binding sites. The level of HCCR-1 expression was increased during the mouse embryogenesis. Expression of phosphatidylinositol 3-kinase (PI3K) in NIH/3T3 cells activated the HCCR-1 promoter. This promoter was also activated by wild type Akt but not by dominant negative Akt in K562 cells. In addition, the level of HCCR-1 was decreased by PI3K inhibitor, LY-294002, in a dose dependent manner. Northern blot analysis revealed that the HCCR-1 gene expression was down-regulated by LY-294002. These results suggest that the HCCR-1 oncogene expression was regulated by the PI3K/Akt signaling pathway. (c) 2006 Elsevier B.V. All rights reserved.
引用
收藏
页码:18 / 26
页数:9
相关论文
共 28 条
[1]   The genetics and genomics of cancer [J].
Balmain, A ;
Gray, J ;
Ponder, B .
NATURE GENETICS, 2003, 33 (Suppl 3) :238-244
[2]   Transcription-dependent and -independent control of neuronal survival by the PI3K-Akt signaling pathway [J].
Brunet, A ;
Datta, SR ;
Greenberg, ME .
CURRENT OPINION IN NEUROBIOLOGY, 2001, 11 (03) :297-305
[3]   The phosphoinositide 3-kinase pathway [J].
Cantley, LC .
SCIENCE, 2002, 296 (5573) :1655-1657
[4]   Matlnspector and beyond: promoter analysis based on transcription factor binding sites [J].
Cartharius, K ;
Frech, K ;
Grote, K ;
Klocke, B ;
Haltmeier, M ;
Klingenhoff, A ;
Frisch, M ;
Bayerlein, M ;
Werner, T .
BIOINFORMATICS, 2005, 21 (13) :2933-2942
[5]   PTEN, but not SHIP and SHIP2, suppresses the PI3K/Akt pathway and induces growth inhibition and apoptosis of myeloma cells [J].
Choi, Y ;
Zhang, J ;
Murga, C ;
Yu, H ;
Koller, E ;
Monia, BP ;
Gutkind, JS ;
Li, WQ .
ONCOGENE, 2002, 21 (34) :5289-5300
[6]   Reduced PTEN expression in breast cancer cells confers susceptibility to inhibitors of the PI3 kinase/Akt pathway [J].
deGraffenried, LA ;
Fulcher, L ;
Friedrichs, WE ;
Grünwald, V ;
Ray, RB ;
Hidalgo, M .
ANNALS OF ONCOLOGY, 2004, 15 (10) :1510-1516
[7]   THE PROTEIN-KINASE ENCODED BY THE AKT PROTOONCOGENE IS A TARGET OF THE PDGF-ACTIVATED PHOSPHATIDYLINOSITOL 3-KINASE [J].
FRANKE, TF ;
YANG, SI ;
CHAN, TO ;
DATTA, K ;
KAZLAUSKAS, A ;
MORRISON, DK ;
KAPLAN, DR ;
TSICHLIS, PN .
CELL, 1995, 81 (05) :727-736
[8]   Phosphoinositide kinases [J].
Fruman, DA ;
Meyers, RE ;
Cantley, LC .
ANNUAL REVIEW OF BIOCHEMISTRY, 1998, 67 :481-507
[9]  
GEERTS D, 2005, CANC LETT, P1
[10]   The HCCR oncoprotein as a biomarker for human breast cancer [J].
Jung, SS ;
Park, HS ;
Lee, IJ ;
Namkoong, H ;
Shin, SM ;
Cho, GW ;
Ha, SA ;
Park, YG ;
Lee, YS ;
Ko, JS ;
Kim, JW .
CLINICAL CANCER RESEARCH, 2005, 11 (21) :7700-7708